ZURICH (Reuters) - Swiss pharmaceutical company Novartis said on Monday its Certican, an immune system drug also known under the names Afinitor and Votubia, showed positive outcomes in a two-year phase III study in liver transplantation. The study, which Novartis said was the largest liver transplant trial to date, confirmed the comparative effectiveness of the treatment and the improved renal ...
